ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 479,40
-0,68%
Dow Jones
39 118,86
-0,12%
DAX
18 235,45
0,17%
Brent Oil
84,85
0,00%
Bitcoin
61 623,99
1,20%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Molecular Partners AG (MOLN)

  7. Molecular Partners AG (MOLN) Actualités

MOLN

Molecular Partners (MOLN)

Molecular Partners AG
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:MOLN
DateHeureSourceTitreSymboleSociété
17/06/202407h00GlobeNewswire Inc.Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation SummitNASDAQ:MOLNMolecular Partners AG
14/06/202416h44Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MOLNMolecular Partners AG
14/06/202407h00GlobeNewswire Inc.Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024NASDAQ:MOLNMolecular Partners AG
11/06/202407h00GlobeNewswire Inc.Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024NASDAQ:MOLNMolecular Partners AG
01/06/202414h00GlobeNewswire Inc.Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024NASDAQ:MOLNMolecular Partners AG
17/05/202412h25Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:MOLNMolecular Partners AG
16/05/202422h00GlobeNewswire Inc.Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 ProgramNASDAQ:MOLNMolecular Partners AG
29/04/202417h00GlobeNewswire Inc.Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action NASDAQ:MOLNMolecular Partners AG
19/04/202417h12GlobeNewswire Inc.Life Science Cares Launches in SwitzerlandNASDAQ:MOLNMolecular Partners AG
17/04/202417h12GlobeNewswire Inc.Molecular Partners Announces All Board Proposals Approved at the Annual General MeetingNASDAQ:MOLNMolecular Partners AG
26/03/202414h26GlobeNewswire Inc.Molecular Partners Publishes Invitation to Annual General Meeting 2024NASDAQ:MOLNMolecular Partners AG
14/03/202421h00GlobeNewswire Inc.Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023NASDAQ:MOLNMolecular Partners AG
01/03/202422h00GlobeNewswire Inc.Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor PresentationsNASDAQ:MOLNMolecular Partners AG
07/01/202422h00GlobeNewswire Inc.Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:MOLNMolecular Partners AG
05/01/202422h00GlobeNewswire Inc.Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin TherapiesNASDAQ:MOLNMolecular Partners AG
14/12/202307h00GlobeNewswire Inc.Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor ConferencesNASDAQ:MOLNMolecular Partners AG
10/12/202318h00GlobeNewswire Inc.Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual MeetingNASDAQ:MOLNMolecular Partners AG
14/11/202307h00GlobeNewswire Inc.Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)NASDAQ:MOLNMolecular Partners AG
03/11/202317h00GlobeNewswire Inc.Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual MeetingNASDAQ:MOLNMolecular Partners AG
02/11/202307h00GlobeNewswire Inc.Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and ExpositionNASDAQ:MOLNMolecular Partners AG
01/11/202307h00GlobeNewswire Inc.Molecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation SummitNASDAQ:MOLNMolecular Partners AG
26/10/202322h00GlobeNewswire Inc.Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin PortfolioNASDAQ:MOLNMolecular Partners AG
13/09/202307h00GlobeNewswire Inc.Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual MeetingNASDAQ:MOLNMolecular Partners AG
24/08/202322h00GlobeNewswire Inc.Molecular Partners Reports H1 2023 Corporate Highlights and FinancialsNASDAQ:MOLNMolecular Partners AG
28/06/202314h35Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:MOLNMolecular Partners AG
28/06/202314h34Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:MOLNMolecular Partners AG
27/06/202307h00GlobeNewswire Inc.Molecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023NASDAQ:MOLNMolecular Partners AG
25/05/202323h01GlobeNewswire Inc.Molecular Partners to Present Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 ASCO Annual MeetingNASDAQ:MOLNMolecular Partners AG
16/05/202322h00GlobeNewswire Inc.Molecular Partners to Participate in RBC Capital 2023 Global Healthcare ConferenceNASDAQ:MOLNMolecular Partners AG
12/05/202312h07Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:MOLNMolecular Partners AG
 Showing the most relevant articles for your search:NASDAQ:MOLN

Dernières Valeurs Consultées

BIT
F19590
Vontobel Financial Produ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés